10906 Federal Register / Vol. 76, No. 39 / Monday, February 28, 2011 / Notices 

included in the Agency’s subsequent 

request for OMB approval of the 

proposed information collection. All 

comments will become a matter of 

public record. 

Dated: February 15, 2011. 

Carolyn M. Clancy, 

Director, AHRQ. 

[FR Doc. 2011–4133 Filed 2–25–11; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[ATSDR–269] 

Proposed Substances To Be Evaluated 

for Set 25 Toxicological Profiles 

AGENCY: Agency for Toxic Substances 

and Disease Registry (ATSDR), 

Department of Health and Human 

Services (HHS). 

ACTION: Request for comments on the 

proposed substances to be evaluated for 

Set 25 toxicological profiles. 

SUMMARY: ATSDR is initiating the 

development of its 25th set of 

toxicological profiles (CERCLA Set 25). 

This notice announces the list of 

proposed substances that will be 

evaluated for CERCLA Set 25 

toxicological profile development. 

ATSDR’s Division of Toxicology and 

Environmental Medicine is soliciting 

public nominations from the list of 

proposed substances to be evaluated for 

toxicological profile development. 

ATSDR also will consider the 

nomination of any additional, nonCERCLA substances that may have 

public health implications, on the basis 

of ATSDR’s authority to prepare 

toxicological profiles for substances not 

found at sites on the National Priorities 

List. The agency will do so in order to 

‘‘* * * establish and maintain inventory 

of literature, research, and studies on 

the health effects of toxic substances’’ 

under CERCLA Section 104(i)(1)(B), to 

respond to requests for consultation 

under section 104(i)(4), and to support 

the site-specific response actions 

conducted by ATSDR, as otherwise 

necessary. 

DATES: Nominations must be submitted 

within 30 days of the publication of this 

notice. 

ADDRESSES: Nominations may be 

submitted electronically. Refer to the 

section Submission of Nominations 

(below) for the specific address. 

SUPPLEMENTARY INFORMATION: The 

Superfund Amendments and 

Reauthorization Act of 1986 (SARA) [42 

U.S.C. 9601 et seq.] amended the 

Comprehensive Environmental 

Response, Compensation, and Liability 

Act of 1980 (CERCLA or Superfund) [42 

U.S.C. 9601 et seq.] by establishing 

certain requirements for ATSDR and the 

U.S. Environmental Protection Agency 

(EPA) with regard to hazardous 

substances most commonly found at 

facilities on the CERCLA National 

Priorities List (NPL). Among these 

statutory requirements is a mandate for 

the Administrator of ATSDR to prepare 

toxicological profiles for each substance 

included on the Priority List of 

Hazardous Substances. This list 

identifies 275 hazardous substances that 

ATSDR and EPA have determined pose 

the most significant current potential 

threat to human health. The availability 

of the revised list of the 275 priority 

substances was announced in the 

Federal Register on March 6, 2008 (73 

FR 12178). For prior versions of the list 

of substances, see Federal Register 

notices dated April 17, 1987 (52 FR 

12866); October 20, 1988 (53 FR 41280); 

October 26, 1989 (54 FR 43619); October 

17, 1990 (55 FR 42067); October 17, 

1991 (56 FR 52166); October 28, 1992 

(57 FR 48801); February 28, 1994 (59 FR 

9486); April 29, 1996 (61 FR 18744); 

November 17, 1997 (62 FR 61332); 

October 21, 1999 (64 FR 56792); October 

25, 2001 (66 FR 54014); November 7, 

2003 (68 FR 63098); and November 29, 

2005 (70 FR 71506). 

Proposed Substances To Be Evaluated 

for Set 25 Toxicological Profiles 

Each year, ATSDR develops a list of 

substances to be considered for 

toxicological profile development; this 

list is compiled from ATSDR’s Priority 

List of Hazardous Substances and from 

previously nominated substances of 

public health concern. The following 74 

proposed substances will be considered 

for Set 25 Toxicological Profile 

development: 

Candidate Substances for Profile 

Development 

1. s,s,s-Tributyl phosphorotrithioate 

(CAS No. 000078–48–8). 

2. 2,4-Dimethylphenol (CAS No. 

000105–67–9). 

3. Bromine (CAS No. 007726–95–6). 

4. Bromodichloroethane (CAS No. 

0000683–53–4). 

5. Butyl benzyl phthalate (CAS No. 

000085–68–7). 

6. Dibenzofuran (CAS No. 000132– 

64–9). 

7. Dicofol (CAS No. 000115–32–2). 

8. Methane (CAS No. 74–82–8). 

9. Neptunium-237 (CAS No. 013994– 

20–2). 

10. Palladium (CAS No. 007440–05– 

3). 

11. Parathion (CAS No. 000056–38–2). 

12. Pentachlorobenzene (CAS No. 

000608–93–5). 

13. Polonium-210 (CAS No. 013981– 

52–7). 

14. Treflan (Trifluralin) (CAS No. 

001582–09–8). 

15. Trichlorofluoroethane (CAS No. 

027154–33–2). 

16. Fluorides (CAS Nos. 007782–41– 

4, 007664–39–3, 016984–48–8). 

17. Selenium (CAS No. 007782–49–2). 

18. Aldrin/Dieldrin (CAS Nos. 

000309–00–2, 000060–57–1). 

19. Beryllium (CAS No. 007440–41– 

7). 

20. Creosote/Coal Tar (CAS Nos. 

008021–39–4, 008007–45–2, 008001– 

58–9, 065996–93–2). 

21. DDT, DDE, DDD (CAS Nos. 

000050–29–3, 000072–55–9, 000072– 

54–8, 000789–02–6, 000053–19, 

003424–82–6). 

22. Di(2-ethylhexyl)phthalate (CAS 

No. 000117–81–7). 

23. Hexachlorobenzene (CAS No. 

000118–74–1). 

24. Methoxychlor (CAS No. 000072– 

43–5). 

25. 1,2–Dichloroethane (CAS No. 

000107–06–2). 

26. Asbestos (CAS Nos. 001332–21–4, 

012001–29–5, 012172–73–5). 

27. Benzidine (CAS No. 000092–87– 

5). 

28. Di-n-butyl phthalate (CAS No. 

000084–74–2). 

29. Pentachlorophenol (CAS No. 

000087–86–5). 

30. Endosulfan (CAS Nos. 000115– 

29–7, 001031–07–8, 000959–98–8, 

033213–65–9). 

31. Ethion (CAS No. 000563–12–2). 

32. Methylene chloride (CAS No. 

000075–09–2). 

33. Polychlorinated biphenyls (CAS 

Nos. 001336–36–3, 011097–69–1, 

011096–82–5, 012672–29–6, 053469– 

21–9, 012767–79–2, 011104–28–2, 

012674–11–2, 011141–16–5, 071328– 

89–7, 026914–33–0). 

34. Toluene (CAS No. 000108–88–3). 

35. Chlorophenols (CAS Nos. 000088– 

06–2, 025167–83–3, 000120–83–2, 

000095–95–4, 000095–57–8, 004901– 

51–3, 000935–95–5, 000058–90–2, 

000106–48–9, 025167–80–0). 

36. Hexachlorocyclopentadiene (CAS 

No. 000077–47–4). 

37. Mercury (CAS Nos. 007439–97–6, 

022967–92–6, 007487–94–7). 

38. 3,3′-Dichlorobenzidine (CAS No. 

000091–94–1). 

39. Chlorinated Dibenzodioxin (CDDs) 

(CAS Nos. 001746–01–6, 034465–46–8, 

037871–00–4, 041903–57–5, 036088– 

22–9, 035822–46–9, 003268–87–9, 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 76, No. 39 / Monday, February 28, 2011 / Notices 10907 

057653–85–7, 039227–28–6, 019408– 

74–3, 040321–76–4). 

40. Chloroethane (CAS No. 000075– 

00–3). 

41. Chloromethane (CAS No. 000074– 

87–3). 

42. Dinitrotoluene (CAS Nos. 025321– 

14–6, 000121–14–2, 000606–20–2). 

43. Chloroform (CAS No. 000067–66– 

3). 

44. Chlorpyrifos (CAS No. 002921– 

88–2). 

45. Endrin (CAS Nos. 000072–20–8, 

053494–70–5, 007421–93–4). 

46. Tetrachloroethylene (CAS No. 

000127–18–4). 

47. Trichloroethylene (CAS No. 

000079–01–6). 

48. 1,2–Dichloroethene (CAS Nos. 

000540–59–0, 000156–60–5, 000156– 

59–2). 

49. Carbon disulfide (CAS No. 

000075–15–0). 

50. 1,1–Dichloroethene (CAS No. 

000075–35–4). 

51. 2,4–Dinitrophenol (CAS No. 

000051–28–5). 

52. 4,6-Dinitro-o-cresol (CAS No. 

000534–52–1). 

53. Disulfoton (CAS No. 000298–04– 

4). 

54. Hexachlorobutadiene (CAS No. 

000087–68–3). 

55. Polycyclic aromatic hydrocarbons 

(CAS No. 130498–29–2). 

56. Acetone (CAS No. 000067–64–1). 

57. Chlordane (CAS Nos. 000057–74– 

9, 005103–71–9, 005103–74–2, 027304– 

13–8, 056641–38–4, 12789–03–6, 

056534–02–2, 039765–80–5, 005103– 

73–1, 003734–48–3). 

58. Chlordecone/Mirex (CAS Nos. 

000143–50–0, 002385–85–5). 

59. Chlorinated Dibenzofurans (CDFs) 

(CAS Nos. 042934–53–2, 039001–02–0, 

038998–75–3, 057117–31–4, 055684– 

94–1, 030402–15–4, 051207–31–9, 

067562–39–4, 072918–21–9, 030402– 

14–3, 057117–44–9, 070648–26–9, 

060851–34–5, 057117–41–6, 055673– 

89–7). 

60. 1,2-Dibromo-3-chloropropane 

(CAS Nos. 000096–12–8, 067708–83–2). 

61. 1,2-Dibromoethane (CAS No. 

000106–93–4). 

62. 2-Hexanone (CAS No. 000591–78– 

6). 

63. 4,4′-Methylene bis(2- 

chloroaniline) (CAS No. 000101–14–4). 

64. N-Nitrosodiphenylamine (CAS 

No. 000086–30–6). 

65. 2-Butanone (CAS No. 000078–93– 

3). 

66. 1,1-Dichloroethane (CAS No. 

000075–34–3). 

67. 1,2-Diphenylhydrazine (CAS No. 

000122–66–7). 

68. Bis(2-chloroethyl) ether (CAS No. 

000111–44–4). 

69. Chlorobenzene (CAS No. 000108– 

90–7). 

70. Radium (CAS Nos. 007440–14–4, 

013982–63–3, 015262–20–1, 013233– 

32–4). 

71. Thorium (CAS Nos. 007440–29–1, 

014269–63–7, 014274–82–9). 

72. 1,1,2-Trichloroethane (CAS No. 

000079–00–5). 

73. N-Nitrosodimethylamine (CAS 

No. 000062–75–9). 

74. N-Nitrosodi-n-propylamine (CAS 

No. 000621–64–7). 

Submission of Nominations for the 

Evaluation Set 25 Proposed Substances: 

Today’s notice invites voluntary public 

nominations for substances not listed in 

this notice. Nominations are most useful 

if they include the full name of the 

nominator, title, affiliation, e-mail 

address, and telephone number. 

ATSDR will evaluate all data and 

information associated with nominated 

substances and will determine the final 

list of substances to be chosen for 

toxicological profile development. 

Substances will be chosen according to 

ATSDR’s specific guidelines for 

selection. These guidelines can be found 

in the Selection Criteria announced in 

the Federal Register on May 7, 1993 

(85FR27286). Please submit 

nominations by any of the following 

methods: 

E-mail: 

tpcandidatecomments@cdc.gov. 

Fax: 770.488.4178. 

Mail: CDR Jessilynn Taylor, 1600 

Clifton Rd., NE., MS F–62, Atlanta, GA 

30333. 

FOR FURTHER INFORMATION CONTACT: For 

further information, please contact 

Commander Jessilynn B. Taylor by 

e-mail at jxt1@cdc.gov or by phone at 

770–488–3313. 

Please ensure that your comments are 

submitted within the specified 

nomination period. Nominations 

received after the closing date will be 

marked as late and may be considered 

only if time and resources permit. 

Ken Rose, 

Director, Office of Policy, Planning and 

Evaluation, National Center for 

Environmental Health/Agency for Toxic 

Substances and Disease Registry. 

[FR Doc. 2011–4327 Filed 2–25–11; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–11–0679] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an 

e-mail to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–5806. Written 

comments should be received within 

30 days of this notice. 

Proposed Project 

Division of Heart Disease and Stroke 

Prevention Management Information 

System—Revision—National Center for 

Chronic Disease Prevention and Health 

Promotion (NCCDPHP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

CDC’s Division of Heart Disease and 

Stroke Prevention (DHDSP) is currently 

approved to collect progress and activity 

information from awardees funded 

through two programs: The National 

Heart Disease and Stroke Prevention 

Program (NHDSPP), and the WellIntegrated Screening and Evaluation for 

Women Across the Nation 

(WISEWOMAN) program. Information is 

collected semi-annually through an 

electronic Management Information 

System (MIS). The current approval is 

scheduled to expire 5/31/2011 (OMB 

No. 0920–0679). 

CDC requests OMB approval to 

continue information collection, with 

changes, for three years. A net reduction 

in the number of respondents will result 

in a net reduction in burden hours. 

Although there will be an increase in 

the number of awardees funded for 

State-based heart disease and stroke 

prevention (HDSP) programs, reporting 

requirements involving the MIS will be 

discontinued for awardees funded 

through the WISEWOMAN program. No 

changes are proposed to the information 

collection instrument, the burden per 

response, or the frequency of 

information collection. 

CDC currently supports populationbased heart disease and stroke 

prevention efforts in selected States and 


srobinson on DSKHWCL6B1PROD with NOTICES